Published: March 9, 2026
Industry Insights from Next Move Strategy Consulting
Lotte Biologics is set to participate in DCAT Week 2026, a premier gathering of the pharmaceutical and biotechnology sectors in New York from March 23 to 26, signaling the company’s push to expand global partnerships and reinforce its presence in the contract development and manufacturing organization (CDMO) market.
At DCAT Week, Lotte Biologics will host meetings at the Lotte New York Palace, engaging with potential partners and exploring business opportunities, particularly in North America. The company plans to showcase the synergy between its Syracuse Bio Campus in New York and the upcoming Songdo Bio Campus in Incheon, scheduled for completion in August. This dual-site model is designed to offer global clients more flexible and reliable manufacturing capabilities, reflecting a strategic commitment to operational excellence across regions.
“Our participation at DCAT Week allows us to connect with industry leaders and identify opportunities to grow our partnerships,” the company said.
Lotte Biologics will also highlight the expansion of its service portfolio through strategic alliances. Notably, its collaboration with US-based cell line development specialist Asimov enables comprehensive “DNA-to-drug-substance” services. This integrated approach reduces the development timeline to approximately 8.5 months from transfection to drug substance release, demonstrating efficiency gains and streamlined manufacturing processes.
Lotte Biologics’ approach of leveraging dual manufacturing sites across the US and South Korea, combined with strategic collaborations, is likely to enhance its competitiveness in the global CDMO market. This strategy not only provides clients with faster and more reliable development timelines but also positions Lotte Biologics as a stronger partner for pharmaceutical companies seeking integrated solutions.
By participating in DCAT Week, Lotte Biologics reinforces its ambition to expand international partnerships and strengthen its position as a key player in the global biologics manufacturing landscape.
Source: Lotte Biologics
Prepared by: Next Move Strategy Consulting
Sanyukta Deb is Digital Marketing Team Lead at Next Move Strategy Consulting, where she has led content strategy and technical SEO for the firm's B2B market research publications for over 2 years. Her editorial process translates NextMSC's primary and secondary research — spanning technology, industrial, and consumer sectors — into commercial narratives, backed by search-intent, keyword, and competitive analysis. She brings 5 years of overall experience in digital marketing and content strategy.
Debashree Dey is Assistant Manager at Next Move Strategy Consulting, where she supports cross-vertical market content and communications across diverse industries for 6 years. Her professional background includes senior content writing, communications, and published manuscript authorship, with experience developing audience-focused business narratives and maintaining clear, consistent messaging. Her role supports research-led content development and editorial quality across NextMSC publications.
This website uses cookies to ensure you get the best experience on our website. Learn more
✖
Add Comment